Abstract
The oxidation of catechol metabolites (2-OH-E1 / 2 / 3 and 4-OH-E1 / 2 / 3) of the endogenous estrogen, i.e. estrone (E1), 17 beta-estradiol (E2), estriol (E3), gives rise to corresponding estrogen-2,3-quinone (E-2,3-Q) and estrogen-3,4- quinone (E-3,4-Q). These reactive estrogen metabolites form covalent adducts with DNA and quinone, and semi-quinone forms of catechol estrogens -induced DNA adducts are found in various target tissues of cancer. Catecholestrogen through redox cycling produce free radicals that also generate various forms of free radical-induced DNA damage. Interaction of estrogen-induced oxidants and estrogen metabolites with DNA has been shown to generate mutations in genes. Hypermethylation at CpG sites in specific regions of the genome coupled with estrogen-induced oxidative damage at CpG sites, predominantly in the hypermethylated regions, could also cause alterations in the genome of cells of estrogen target organs that lead to mutation of genes. Increasing evidence shows that estrogen through oxidative stress and / or its metabolic products induce genetic alteration affecting both the structural as well as function of the genes. Presence of multiple forms of genetic alterations such as chromosomal aberrations, gene amplifications, DNA sequence variations, and DNA microsatellite instability in estrogen-related cancers and induction of similar genetic events by estrogen both in vivo and in vitro indicate that genetic alterations play an important role in estrogen-related carcinogenesis. This review highlights the current understanding of the estrogen-induced genetic alterations and their significance in estrogen-related carcinogenesis.
Keywords: estrogen, reactive oxygen (nitrogen) species, genetic alterations, carcinogenicity
Current Genomics
Title: Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity
Volume: 5 Issue: 3
Author(s): D. Roy and K. P. Singh
Affiliation:
Keywords: estrogen, reactive oxygen (nitrogen) species, genetic alterations, carcinogenicity
Abstract: The oxidation of catechol metabolites (2-OH-E1 / 2 / 3 and 4-OH-E1 / 2 / 3) of the endogenous estrogen, i.e. estrone (E1), 17 beta-estradiol (E2), estriol (E3), gives rise to corresponding estrogen-2,3-quinone (E-2,3-Q) and estrogen-3,4- quinone (E-3,4-Q). These reactive estrogen metabolites form covalent adducts with DNA and quinone, and semi-quinone forms of catechol estrogens -induced DNA adducts are found in various target tissues of cancer. Catecholestrogen through redox cycling produce free radicals that also generate various forms of free radical-induced DNA damage. Interaction of estrogen-induced oxidants and estrogen metabolites with DNA has been shown to generate mutations in genes. Hypermethylation at CpG sites in specific regions of the genome coupled with estrogen-induced oxidative damage at CpG sites, predominantly in the hypermethylated regions, could also cause alterations in the genome of cells of estrogen target organs that lead to mutation of genes. Increasing evidence shows that estrogen through oxidative stress and / or its metabolic products induce genetic alteration affecting both the structural as well as function of the genes. Presence of multiple forms of genetic alterations such as chromosomal aberrations, gene amplifications, DNA sequence variations, and DNA microsatellite instability in estrogen-related cancers and induction of similar genetic events by estrogen both in vivo and in vitro indicate that genetic alterations play an important role in estrogen-related carcinogenesis. This review highlights the current understanding of the estrogen-induced genetic alterations and their significance in estrogen-related carcinogenesis.
Export Options
About this article
Cite this article as:
Roy D. and Singh P. K., Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity, Current Genomics 2004; 5 (3) . https://dx.doi.org/10.2174/1389202043349471
DOI https://dx.doi.org/10.2174/1389202043349471 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets Cisplatin Changes Expression of SEMA3B in Endometrial Cancer
Current Pharmaceutical Biotechnology Targeting Hormonal Signaling Pathways in Castration Resistant Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Treatment of Uterine Carcinomas
Current Cancer Therapy Reviews Telomerase Therapeutics for Degenerative Diseases
Current Molecular Medicine Involvement of Nucleotide Excision and Mismatch Repair Mechanisms in Double Strand Break Repair
Current Genomics The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Current Medicinal Chemistry Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents
Current Medicinal Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design SERMs: Evolutionary Chemistry, Revolutionary Biology
Current Pharmaceutical Design Recent Advances in Gene Therapy of Endometriosis
Recent Patents on DNA & Gene Sequences Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Novel Fluorine Boron Hybrid Complex as Potential Antiproliferative Drugs on Colorectal Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Targeted Regulation of PI3K/Akt/mTOR/NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Physiology of Androgens and Androgen Testosterone Therapy in Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Diagnostic Value of MicroRNA 21 in Endometrial Cancer and Benign Lesions and its Differential Expression with Clinicopathological Parameters
MicroRNA Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy
Current Molecular Pharmacology Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry